We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice.
- Authors
Ali, Amar; Bain, Steve; Hicks, Debbie; Newland Jones, Phillip; Patel, Dipesh C.; Evans, Marc; Fernando, Kevin; James, June; Milne, Nicola; Viljoen, Adie; Wilding, John
- Abstract
In the original publication, Table 2 note was incorrectly published as "SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m2. Individuals already treated with canagliflozin or empagliflozin who demonstrate renal decline may continue treatment until eGFR reaches < 45 mL/min/1.73 m2".
- Subjects
EVIDENCE; EMPAGLIFLOZIN; THERAPEUTICS
- Publication
Diabetes Therapy, 2019, Vol 10, Issue 5, p1623
- ISSN
1869-6953
- Publication type
Correction Notice
- DOI
10.1007/s13300-019-0670-y